The NanoRam™ is a state-of-the-art compact Raman handheld spectrometer and integrated computing system for material identification and verification within cGMP compliant facilities. Designed for use by non-specialists, the NanoRam is easy to use and operates single-handedly, weighing less than 2.2lbs. It allows rapid development of standardized and validated methods to facilitate inspection for purity and quality, making it the ideal choice for pharmaceutical, chemical, and material identification, whether in the lab, the warehouse, the loading dock or the field. The NanoRam is the only handheld Raman device that features a temperature controlled detector, providing superior data quality and unprecedented system stability. Coupling this proprietary thermoelectric cooling with our patented CleanLaze® laser stabilization technology and high speed micro-processor, it provides
laboratory performance in the palm of your hand. The first rate signal reduces the need for further testing, therefore decreasing production costs and escalating productivity, all at the same time.
www.nanoram.com
|
|
|
|
The Society of Biology is the largest professional body for the biological sciences in the United Kingdom – representing over 11,500 individual life scientists and 90 member organisations. Membership of the Society will help you stay up to date with what is happening across the life sciences and provide you with additional recognition for your skills and experience. Members can become Chartered through the Society and we offer two professional awards: Chartered Biologist (CBiol) and Chartered Scientist (CSci). Which award is best for you depends on your particular job role, circumstances and personal self-identification as a biologist or a scientist.
Click here for more information about the benefits of membership >>
|
|
|
|
|
|
|
|
|
|
|
|
Sanofi Pasteur has announced the online publication in The Lancet of clinical study results showing the ability of its vaccine candidate to protect against dengue fever caused by three dengue virus types. The results of the world’s first efficacy study confirm the excellent safety profile of Sanofi Pasteur’s dengue vaccine candidate.
Read the full story >>
|
|
 |
|
|
|
|
|
 |
|
Biogen Idec sells BENLYSTA royalty rights to DRI Capital managed fund
Biogen Idec and DRI Capital announced that Biogen Idec has sold to a DRI Capital managed fund its royalty and other rights relating to BENLYSTA® (belimumab) to which Biogen Idec is entitled pursuant to a license agreement with Human Genome Sciences, Inc. and Glaxo Group Limited...
|
|
 |
|
Lilly announces results from lung cancer study
Eli Lilly and Company announced that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer...
|
|
 |
|
Abbott to collaborate with Astellas in CMV Vaccine Trial
Abbott has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant patients...
|
|
|
|
|
|
Handheld Raman: Cut costs, improve efficiency & move toward 100% testing
 |
|
In this one hour instructional webinar we will discuss how handheld Raman reduces costs and improves efficiency, the move to mandatory 100% testing of incoming raw materials, and recent developments in handheld Raman technology:
-
The move to mandatory 100% testing of incoming raw materials
Ravi Kalyanaraman PhD, Principal Scientist, Bristol Myers Squibb
-
How handheld Raman improves efficiency
John Kauffman, Research Chemist at FDA
Find out more >>
|
|
|
|
Conferences, events & exhibitions:
Design Validation, Verification, and Risk Analysis for Medical Device Professionals
12 - 13 September 2012 Berlin, Germany
Validation of Computer Systems
17 - 18 September 2012 Dublin, Ireland
The EU Clinical Trial Directive
17 - 18 September 2012 Dublin, Ireland
ADME, PK/TK, and Drug Metabolism in Drug Discovery and Development
17 - 19 September 2012 Dublin, Ireland
The Drug Development Process – From Discovery to Commercialisation
19 - 21 September 2012 Dublin, Ireland
11th Annual Biological Production Forum 2012
24 - 26 September 2012 Dusseldorf, Germany
MipTec 2012
24 - 27 September 2012 Basel, Switzerland
Lab-on-a-Chip World Congress
25 - 26 September 2012 San Diego, USA
Single Cell Analysis Summit
25 - 26 September 2012 San Diego, USA
Molecular Diagnostics World Congress
25 - 26 September 2012 San Diego, USA
Quantitative Bioanalysis using LC-MS for Pharma Industry
25 - 26 September 2012 London, UK
11th Annual ELNs & Advanced Laboratory Solutions
25 - 27 September, 2012 Grand Visconti Palace, Milan, Italy
Microarray World Congress
25 - 26 September 2012 San Diego, USA
Take Time to Make Time
26 September 2012 Dublin, Ireland
Biomarkers 2012
26 September 2012 London, UK
1st International Genomics Research Asia
13 - 14 November 2012 Daejong, South Korea
|
|
Pharmaceuticals: Global Industry Almanac
The global pharmaceuticals market grew by 3.6% in 2010 to reach a value of $733,104.8 million. In 2015, the global pharmaceuticals market is forecast to have a value of $981,050.8 million, an increase of 33.8% since 2010.
The “Patent Cliff”: How Pfizer has responded to the loss of its best-selling drug
The global pharmaceuticals market was worth $733bn in 2010. With the patents of many of the world’s best-selling drugs expiring, the market is currently in the middle of a “patent cliff”. This Case Study looks at the various routes companies are taking in order to minimize the adverse effects caused by this “patent cliff”.
OTC Pharmaceuticals: Global Industry Almanac 2011
OTC Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Johnson & Johnson Case Study: Remicade, a Biotech Blockbuster
Remicade is a drug used in treating a variety of immune system diseases, and its active ingredient is produced through biotechnology. Johnson & Johnson reported Remicade sales of $4.6bn in 2010, and the drug is the best-selling “biologic” in the world. This case study examines its long journey from an academic research laboratory to a leading position in the pharmaceutical market.
|
|
|
